Pre-Hospital Administration of Remdesivir During a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak in a Skilled Nursing Facility

Dunay, Megan; McClain, Sarah L; Holloway, Rick L; Norris, Sarah L.; Randall, Talie Bendixsen; Mohr, Caitlin E; Sasaki, Brent H; Coones, Joseph A; Vietri, Nicholas J.

doi:10.1093/cid/ciab715

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the final results of ACCT-1 and WHO solidarity randomized clinical trials suggest that remdesivir offers no substantial benefit to ventilated COVID-19 patients but aids in reducing death or the need for ventilation in other hospital cases, especially in patients requiring low-flow supplemental oxygen [32,37,38]. Additionally, multiple observational studies, but not all, have shown an association with remdesivir use in hospitalized patients and reduced mortality [35,36,[39][40][41][42][43][44][45][46][47]. Finally, a systematic review and individual patient data meta-analysis of eight randomized clinical trials (RCTs) consisting of 10,480 patients hospitalized with COVID-19 found a significant reduction in mortality with remdesivir use compared to non-use (OR 0.88; 95% CI, 0.78 to 1.00; p = 0.045) [38].…”

Section: Remdesivir's Role In the Treatment Of Covid-19 In Hospitaliz...mentioning

confidence: 99%

Remdesivir and the Liver: A Concise Narrative Review of Remdesivir-Associated Hepatotoxicity in Patients Hospitalized Due to COVID-19

FakhriRavari,

Malakouti

2024

Pharmacoepidemiology

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 has infected millions of people, but about 20% of infected individuals do not develop symptoms. COVID-19 is an inflammatory disease that affects a portion of individuals infected with the virus and it is associated with liver injury and other complications, leading to hospitalization, critical illness, and death. Remdesivir is an antiviral agent used for the treatment of hospitalized patients with COVID-19 to improve the time to recovery, reduce the duration of mechanical ventilation, decrease the need for supplemental oxygen, and decrease the risk of mortality. Remdesivir-associated hepatotoxicity has been observed as increased transaminases more than five times the upper limit of normal in hospitalized patients with COVID-19, but causality has not been proven. It is generally difficult to distinguish between remdesivir-associated hepatotoxicity and COVID-19-induced hepatotoxicity. The purpose of this review is to evaluate the evidence for remdesivir-associated hepatotoxicity. Current evidence suggests that elevated liver enzymes in hospitalized COVID-19 patients are more likely to be due to the infection than remdesivir, and a 5-day course of remdesivir seems to be safe in regard to hepatotoxicity.

show abstract

Section: Remdesivir's Role In the Treatment Of Covid-19 In Hospitaliz...mentioning

confidence: 99%

Remdesivir and the Liver: A Concise Narrative Review of Remdesivir-Associated Hepatotoxicity in Patients Hospitalized Due to COVID-19

FakhriRavari,

Malakouti

2024

Pharmacoepidemiology

View full text Add to dashboard Cite

show abstract

Remdesivir and the Liver: A Concise Narrative Review of Remdesivir-Associated Hepatotoxicity in Patients Hospitalized Due to COVID-19

FakhriRavari,

Malakouti

2024

Preprint

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 infects many people, but many infected individuals do not develop symptoms. COVID-19 is an inflammatory disease that affects a portion of individuals infected with the virus, and it is associated with liver injury and other complications leading to hospitalization, critical illness, and death. Remdesivir is an antiviral agent used for treatment of hospitalized patients with COVID-19 to improve time to recovery, reduce duration of mechanical ventilation, decrease the need for supplemental oxygen, and decrease the risk of mortality. Remdesivir-associated hepatotoxicity has been observed as increased transaminases more than 5 times the upper limit of normal in hospitalized patients with COVID-19 but causality has not been proven. It is generally difficult to distinguish between remdesivir-associated hepatotoxicity and COVID-19-induced hepatotoxicity. The purpose of this review is to evaluate the evidence for remdesivir-associated hepatotoxicity. Current evidence suggests that elevated liver enzymes in hospitalized COVID-19 patients are more likely to be due to the infection than remdesivir and that a 5-day course of remdesivir seems to be safe in regards to hepatotoxicity.

show abstract

Pre-Hospital Administration of Remdesivir During a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak in a Skilled Nursing Facility

Cited by 2 publications

References 13 publications

Remdesivir and the Liver: A Concise Narrative Review of Remdesivir-Associated Hepatotoxicity in Patients Hospitalized Due to COVID-19

Remdesivir and the Liver: A Concise Narrative Review of Remdesivir-Associated Hepatotoxicity in Patients Hospitalized Due to COVID-19

Remdesivir and the Liver: A Concise Narrative Review of Remdesivir-Associated Hepatotoxicity in Patients Hospitalized Due to COVID-19

Contact Info

Product

Resources

About